In clinical practice, CSF is already used for the amyloid-tau-neurodegeneration (ATN) classification system of AD patients, which assesses levels of amyloid-β (A) and phosphorylated tau (T), along with the evaluation of neurodegeneration (N) by brain imaging, to biologically define AD and distinguish it from other dementias. Here, MAPT is linked to dementia.